WASHINGTON (Indiana’s NewsCenter) - The drug maker of a best-selling cancer medicine is scrambling for government approval again.
The FDA ruled against using "Avastin" for breast cancer because it is ineffective.
Roche officials are calling on the federal government to re-think its decision.
The FDA ruled that Avastin does not extend or improve the life of breast cancer patients.
However, in Tuesday’s hearing, there will be emotional testimony from the women who rely on the drug to treat their advanced breast cancer.
What are your thoughts CLICK HERE to leave us a "QUESTION OF THE DAY” comment.
© Copyright 2014, A Granite Broadcasting Station. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.